Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0029463 (osteosarcoma)
 16,637 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effects of gossypol were examined in several cell lines including hamster V79 lung fibroblasts, WB-344 rat liver oval cells, human osteosarcoma cells and LC540 rat Leydig cells. Gossypol had little cytotoxic effects in these cell lines except at high concentrations. Plasma membrane integrity was maintained in LC540 except at high concentrations of gossypol. Gossypol did not increase mutational frequency as examined by the hypoxanthine guanine phosphoribosyl transferase and Na+,K(+)-ATPase loci in V79 cells. Gossypol inhibited gap junctional intercellular communication in some but not all of the cell lines. This selectivity might be the basis for the sensitivity of certain tissues or organs to gossypol. For example, the Leydig cell, which is the component of a target organ system for toxicity, was sensitive to gossypol. Modulation of gap junctional functions might play a significant role in both pharmacological and toxicological effects of gossypol.
 ...
PMID:The modulation of gap junctional communication by gossypol in various mammalian cell lines in vitro. 236 80

Osteosarcoma (OS) is the most common primary malignant bone tumor and mainly affects children and adolescents. The OS five-year survival rate remains very low. Thus, novel therapeutic protocols for the treatment of OS are needed. Several approaches targeting deregulated signaling pathways have been proposed. The antitumoral effects of polyphenols, which are naturally occurring compounds with potent antioxidant and anti-inflammatory activity, have been investigated in different tumors. Gossypol, which is a natural polyphenolic aldehyde isolated from the seeds of the cotton plant, has been shown to exert antitumoral activity in leukemia and lymphoma and in breast, head and neck, colon and prostate cancers. Therefore, in this study, we evaluated the effect of AT-101, which is the (-) enantiomer and more active form of gossypol, on the growth of human and murine OS cells in vitro and in vivo. Several clinical trials employing AT-101 have been performed, and some clinical trials are ongoing. Our results showed for the first time that AT-101 significantly inhibits OS cell growth in a dose- and time-dependent manner, inducing apoptosis and necrosis and partially activating autophagy. Our results demonstrated that AT-101 inhibits prosurvival signaling pathways depending on Akt, p38 MAPK and JNK. In addition, treatment with AT-101 increases the survival of OS-bearing mice. Overall, these results suggest that AT-101 is a candidate chemo-supportive molecule for the development of novel chemotherapeutic protocols for the treatment of OS.
 ...
PMID:In vivo and in vitro inhibition of osteosarcoma growth by the pan Bcl-2 inhibitor AT-101. 3126 66